Cdc20 is phosphorylated during mitosis so this epitope is a good marker of cell cycle progression
| Inventor | Institute |
|---|---|
| Julian Gannon | Cancer Research UK, London Research Institute: Clare Hall Laboratories |
| SKU: | 151753 |
|---|---|
| Product description: | Cdc20 (fizzy protein) is associated with the activation of the anaphase-promoting complex at the onset of anaphase. Cdc20 is phosphorylated during mitosis so this epitope is a good marker of cell cycle progression |
| Alternate name: | APC/C activator protein CDC2; Cell division control protein 2; YGL116W; Cell Division Cycle 2; P55CDC; CDC2 Cell Division Cycle 2 Homolog; Cell Division Cycle 2 Homolog; BA276H19.3; CDC2A |
| Conjugation: | Unconjugated |
| Isotype: | Not Known |
| Molecular weight: | 55 kDa |
| Immunogen: | GPKMQGpTPSRAG. pT represents phosphorylated Thr79. |
| Myeloma used: | Sp2/0-Ag14 |
| Cat. #: | 151753 |
|---|---|
| Provenance and Ownership: | The Anti-Phospho-cdc20 (Thr79) [BT2.1] is owned by Cancer Research UK. CancerTools supplies the Anti-Phospho-cdc20 (Thr79) [BT2.1] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-Phospho-cdc20 (Thr79) [BT2.1] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology |
| Application: | ELISA ; WB |
| Target: | cdc20 |
| Reactivity: | Xenopus laevis |
| Clone: | BT2.1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | Cdc20 (fizzy protein) is associated with the activation of the anaphase-promoting complex at the onset of anaphase. Cdc20 is phosphorylated during mitosis so this epitope is a good marker of cell cycle progression |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Labit et al. 2012. EMBO J. 31(15):3351-62. PMID: 22713866. Dephosphorylation of Cdc20 is required for its C-box-dependent activation of the APC/C. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.